icon-folder.gif   Conference Reports for NATAP  
 
  Digestive Disease Week (DDW)
May 18-21, 2013
Orlando, FL
Back grey_arrow_rt.gif
 
 
 
Response to 3 DAAs + RBV by Patient Characteristics: INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333, AND RIBAVIRIN ACHIEVE HIGH SUSTAINED VIROLOGIC RESPONSE 12 WEEKS POST-TREATMENT (SVR12) RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 REGARDLESS OF RACE, ETHNICITY, OR OTHER BASELINE CHARACTERISTICS
 
 
  Reported by Jules Levin
Digestive Disease Week (DDW) 2013
Orlando, FL, May 20, 2013
 
Maribel Rodriguez-Torres1, Frederick A. Nunes2, Daniel E. Cohen3, Wangang Xie3, Christal Marincic3, Amit Khatri3, Tami Pilot-Matias3, Thomas Podsadecki3, and Barry Bernstein3
1: Fundación de Investigación de Diego, San Juan, PR, 2: Univeristy of Pennsylvania Health System, Philadelphia, PA, 3: AbbVie Inc., North Chicago, IL

DDW1.gif

DDW2.gif

DDW3.gif

DDW4.gif

DDW5.gif

DDW6.gif

DDW7.gif